1.230EUR-2.38%Mkt Cap: 16.77M EURP/E: —Last update: 2026-06-01
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-speci…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap16.77M EUR
Enterprise Value15.03M EUR
Revenue (TTM)2.08M EUR
Gross Profit2.08M EUR
Net Income (TTM)-6.43M EUR
Revenue/Share0.1520 EUR
Last Price1.230 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees16
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0014007ZB4
Valuation
P/E (Trailing)—
P/E (Forward)7.41
PEG—
EV/EBITDA-2.46
EV/Revenue7.21
P/S8.24
P/B3.87
EPS (TTM)-0.47
EPS (Forward)0.17
52W Range
0.672034% of range2.300
52W High2.300 EUR
52W Low0.6720 EUR
Profitability
Gross Margin100.00%
Oper. Margin-172.75%
EBITDA Margin-293.14%
Profit Margin0.00%
ROE-144.94%
ROA-53.40%
Growth
Revenue Growth-17.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.35M EUR
CapEx (TTM)4.00K EUR
FCF Margin-148.83%
FCF Yield-18.49%
Net Debt-2.10M EUR
Net Debt/EBITDA0.34
Balance Sheet
Debt/Equity1.49
Current Ratio4.40
Quick Ratio4.13
Book Value/Sh0.3260 EUR
Cash/Share0.6400 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.13.63M
Float3.89M
Insiders36.44%
Institutions27.52%
Technical
SMA 501.279 (-3.8%)
SMA 2001.233 (-0.2%)
Beta0.59
S&P 52W Chg27.94%
Avg Vol (30d)25.83K
Avg Vol (10d)25.30K
Technical Indicators
RSI (14)52.7
MACD-0.0135
MACD Signal-0.0195
MACD Hist.+0.0060
BB Upper1.296 EUR
BB Middle1.233 EUR
BB Lower1.170 EUR
BB Width10.16%
ATR (14)0.0633 EUR
Vol Ratio (20d)3.94x